Abstract
On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.
Highlights
On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency
Effective therapeutic window for convalescent plasma (CCP) administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP
Presented with state of emergency accompanied by no available treatment and scarce medical resources; multiple centers around the world instituted CCP in a relatively timely manner previously shown effective during the SARS-CoV and Spanish Flu pandemic [3]
Summary
On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Available treatment was limited to supportive care as no approved therapy or vaccination was available. This treatment vacuum motivated the utilization of convalescent plasma infusion to complement the antibody response. Passive immunization has been successfully used to treat infectious diseases since the 1890s [1,2]. Convalescent plasma (CP) was used to treat Spanish Influenza A (H1N1), severe acute respiratory syndrome in 2003 caused by SARS-associated coronavirus (SARS-CoV), and Influenza A pandemic in 2009 [3,4]. Donated CP administered to an infected individual anticipating transfused antibodies would affect sufficient passive immunity to reduce symptoms and mortality risk
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
